title: Multiple facial basal cell carcinomas in xeroderma pigmentosum treated with topical imiquimod 5% cream.
abstract: Xeroderma pigmentosum (XP) is an autosomal recessive disease characterized by solar sensitivity, photophobia, early onset of freckling, and solar-induced cutaneous neoplastic changes. Management of patients with XP is a therapeutic challenge as they usually develop multiple cutaneous malignancies, making surgical therapy difficult, and continue to form skin malignancies at a high rate. We describe a 30-year-old Chinese man with XP who had been previously treated with excision and dermatoplasty. Upon recurrence of multiple superficial, ulcerative, and pigmented lesions, imiquimod 5% cream was recommended for 4 months. His multiple facial lesions demonstrated an excellent response to topical imiquimod 5% cream with minor side effects. This favorable response indicates that topical application of imiquimod 5% cream is an effective means of treating multiple basal cell carcinomas in XP.
authors.affiliation: Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.|Department of Dermatology, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, China.
authors.forename: Jian-Qiang
authors.initials: JQ
authors.lastname: Yang
authors.affiliation: Department of Dermatology, Yongkang Hospital of Traditional Chinese Medicine, Yongkang, Zhejiang, China.
authors.forename: Xian-Yu
authors.initials: XY
authors.lastname: Chen
authors.affiliation: Family Medicine Resident, O'Connor Hospital, San Jose, CA, USA.
authors.forename: Michelle Yixiao
authors.initials: MY
authors.lastname: Engle
authors.affiliation: Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
authors.forename: Jian-You
authors.initials: JY
authors.lastname: Wang
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000150:complications / Q000188:drug therapy*; D005153:Facial Neoplasms / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000150:complications / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000150:complications / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy*; D014983:Xeroderma Pigmentosum / Q000150:complications*
chemical_list: D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod
keywords: basal cell carcinoma; imiquimod; xeroderma pigmentosum